Screening active compounds from Garcinia species native to china reveals novel compounds targeting the STAT/JAK signaling pathway

BioMed Research International

Volumn 2015, Issue , 2015, Pages

  Xu, Linfeng ^a,b,c   Lao, Yuanzhi ^a,b   Zhao, Yanhui ^c   Qin, Jian ^c   Fu, Wenwei ^a,b   Zhang, Yingjia ^c   Xu, Hongxi ^a,b  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b Engineering Research Center of Shanghai   (China)

^c Shanghai ChemPartner Co Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 7; JANUS KINASE 2; MOLECULAR SCAFFOLD; NATURAL PRODUCT; STAT3 PROTEIN; XANTHONE DERIVATIVE; JAK2 PROTEIN, HUMAN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE; CELL CYCLE ARREST; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CELL VIABILITY ASSAY; CHEMICAL STRUCTURE; CONTROLLED STUDY; DRUG DEVELOPMENT; ENZYME ACTIVITY; ENZYME ASSAY; FLOW CYTOMETRY; GARCINIA; HUMAN; IC50; MEDICINAL PLANT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; CHEMISTRY; CHINA; DRUG EFFECTS; GENETICS; METABOLISM; NEOPLASMS; PATHOLOGY; TUMOR CELL LINE;

GARCINIA;

APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CHINA; GARCINIA; HUMANS; JANUS KINASE 2; NEOPLASMS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR;

EID: 84930959573     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2015/910453     Document Type: Article

References (34)

1. D. J. Newman and G. M. Cragg, "Natural products as sources of new drugs over the 30 years from 1981 to 2010, " Journal of Natural Products, vol. 75, no. 3, pp. 311-335, 2012.
2. A. D. Kinghorn, Y. W. Chin, and S. M. Swanson, "Discovery of natural product anticancer agents from biodiverse organisms, " CurrentOpinion in Drug Discovery and Development, vol. 12, no. 2, pp. 189-196, 2009.
3. M. Feher and J. M. Schmidt, "Property distributions: Differences between drugs, natural products, and molecules from combinatorial chemistry, " Journal of Chemical Information and Computer Sciences, vol. 43, no. 1, pp. 218-227, 2003.
4. D. Hanahan and R. A. Weinberg, "Hallmarks of cancer: the next generation, " Cell, vol. 144, no. 5, pp. 646-674, 2011.
5. K.-H. Lee, "Discovery and development of natural productderived chemotherapeutic agents based on a medicinal chemistry approach, " Journal of Natural Products, vol. 73, no. 3, pp. 500-516, 2010.
6. N. Anantachoke, P. Tuchinda, C. Kuhakarn, M. Pohmakotr, and V. Reutrakul, "Prenylated caged xanthones: chemistry and biology, " Pharmaceutical Biology, vol. 50, no. 1, pp. 78-91, 2012.
7. W.-W. Fu, H.-S. Tan, and H.-X. Xu, "Research progress of chemistry and anti-cancer activities of natural products from Chinese garcinia plants, " Yao Xue Xue Bao, vol. 49, no. 2, pp. 166-174, 2014.
8. Q.-B. Han, Y.-L. Wang, L. Yang, et al., "Cytotoxic polyprenylated xanthones from the resin of Garcinia hanburyi, " Chemical and Pharmaceutical Bulletin, vol. 54, no. 2, pp. 265-267, 2006.
9. S. X. Huang, C. Feng, Y. Zhou, et al., "Bioassay-guided isolation of xanthones and polycyclic prenylated acylphloroglucinols fromGarcinia oblongifolia, " Journal of Natural Products, vol. 72, no. 1, pp. 130-135, 2009.
10. X.-M. Gao, T. Yu, F. S. F. Lai, et al., "Identification and evaluation of apoptotic compounds from Garcinia paucinervis, " Bioorganic & Medicinal Chemistry, vol. 18, no. 14, pp. 4957-4964, 2010.
11. X. Liu, T. Yu, X. M. Gao, et al., "Apoptotic effects of polyprenylated benzoylphloroglucinol derivatives from the twigs of garcinia multiflora, " Journal of Natural Products, vol. 73, no. 8, pp. 1355-1359, 2010.
12. Y. Lao, G. Wan, Z. Liu, et al., "The natural compound oblongifolinCinhibits autophagic flux and enhances antitumor efficacy of nutrient deprivation, " Autophagy, vol. 10, no. 5, pp. 736-749, 2014.
13. H. Zhang, L. Tao, W.-W. Fuet al., "Prenylatedbenzoylphloroglucinols and xanthones from the leaves of Garcinia oblongifolia with antienteroviral activity, " Journal of Natural Products, vol. 77, no. 4, pp. 1037-1046, 2014.
14. D. J. Newman, "Natural products as leads to potential drugs: an old process or the new hope for drug discovery?" Journal of Medicinal Chemistry, vol. 51, no. 9, pp. 2589-2599, 2008.
15. Q. B. Han and H. X. Xu, "Caged Garcinia xanthones: development since 1937, " Current Medicinal Chemistry, vol. 16, no. 28, pp. 3775-3796, 2009.
16. S. Prasad, M. K. Pand ey, V. R. Yadav, and B. B. Aggarwal, "Gambogic acid inhibits STAT3 phosphorylation through activation of protein tyrosine phosphatase SHP-1: potential role in proliferation and apoptosis, " Cancer Prevention Research, vol. 4, no. 7, pp. 1084-1094, 2011.
17. K. Nakano and K. H. Vousden, "PUMA, a novel proapoptotic gene, is induced by p53, " Molecular Cell, vol. 7, no. 3, pp. 683-694, 2001.
18. J. Yu, L. Zhang, P. M. Hwang, K. W. Kinzler, and B. Vogelstein, "PUMA induces the rapid apoptosis of colorectal cancer cells, " Molecular Cell, vol. 7, no. 3, pp. 673-682, 2001.
19. E. Oda, R. Ohki, H. Murasawa, et al., "Noxa, a BH3-onlymember of the Bcl-2 family and cand idate mediator of p53-induced apoptosis, " Science, vol. 288, no. 5468, pp. 1053-1058, 2000.
20. L. Brown, P. P. Ongusaha, H. G. Kim, et al., "CDIP, a novel pro-apoptotic gene, regulates TNFβ-mediated apoptosis in a p53-dependent manner, " The EMBO Journal, vol. 26, no. 14, pp. 3410-3422, 2007.
21. K. Leslie, S. P. Gao, M. Berishaj, et al., "Differential interleukin-6/Stat3 signaling as a function of cellular context mediates Rasinduced transformation, " Breast Cancer Research, vol. 12, no. 5, p. R80, 2010.
22. J. F. Bromberg, C. M. Horvath, D. Besser, W. W. Lathem, and J. E. Darnell Jr., "Stat3 activation is required for cellular transformation by v-src, " Molecular & Cellular Biology, vol. 18, no. 5, pp. 2553-2558, 1998.
23. A. Vultur, R. Arulanand am, J. Turkson, G. Niu, R. Jove, and L. Raptis, "Stat3 is required for full neoplastic transformation by the Simian Virus 40 large tumor antigen, " Molecular Biology of the Cell, vol. 16, no. 8, pp. 3832-3846, 2005.
24. J. V. Alvarez, H. Greulich, W. R. Sellers, M. Meyerson, and D. A. Frank, "Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancerassociated mutations of the epidermal growth factor receptor, " Cancer Research, vol. 66, no. 6, pp. 3162-3168, 2006.
25. R. Chiarle, W. J. Simmons, H. Cai, et al., "Stat3 is required for ALK-mediated lymphomagenesis and provides a possible therapeutic target, " Nature Medicine, vol. 11, no. 6, pp. 623-629, 2005.
26. D. E. Levy and J. E. Darnell Jr., "STATs: transcriptional control and biological impact, " Nature Reviews Molecular Cell Biology, vol. 3, no. 9, pp. 651-662, 2002.
27. J. Bromberg and T. C. Wang, "Inflammation and cancer: IL-6 and STAT3 complete the link, " Cancer Cell, vol. 15, no. 2, pp. 79-80, 2009.
28. S. Bhattacharya, R. M. Ray, and L. R. Johnson, "STAT3-mediated transcription of Bcl-2, Mcl-1 and C-IAP2 prevents apoptosis in polyamine-depleted cells, " Biochemical Journal, vol. 392, part 2, pp. 335-344, 2005.
29. M. Berishaj, S. P. Gao, S. Ahmed, et al., "Stat3 is tyrosinephosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer, " Breast Cancer Research, vol. 9, no. 3, article R32, 2007.
30. Z. T. Schafer and J. S. Brugge, "IL-6 involvement in epithelial cancers, " Journal of Clinical Investigation, vol. 117, no. 12, pp. 3660-3663, 2007.
31. B. Ancrile, K.-H. Lim, and C. M. Counter, "Oncogenic Rasinduced secretion of IL6 is required for tumorigenesis, " Genes & Development, vol. 21, no. 14, pp. 1714-1719, 2007.
32. S. P. Gao, K. G. Mark, K. Leslie, et al., "Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas, " The Journal of Clinical Investigation, vol. 117, no. 12, pp. 3846-3856, 2007.
33. V. Sriuranpong, J. I. Park, P. Amornphimoltham, V. Patel, B. D. Nelkin, and J. S. Gutkind, "Epidermal growth factor receptor-independent constitutive activation of STAT3 in head and neck squamous cell carcinoma is mediated by the autocrine/paracrine stimulation of the interleukin 6/gp130 cytokine system, " Cancer Research, vol. 63, no. 11, pp. 2948-2956, 2003.
34. L. Song, B. Rawal, J. A. Nemeth, and E. B. Haura, "JAK1 activates STAT3 activity in non-small-cell lung cancer cells and IL-6 neutralizing antibodies can suppress JAK1-STAT3 signaling, " Molecular CancerTherapeutics, vol. 10, no. 3, pp. 481-494, 2011.